These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8889983)

  • 1. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
    Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
    J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended ganciclovir prophylaxis in lung transplantation.
    Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
    J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.
    Hertz MI; Jordan C; Savik SK; Fox JM; Park S; Bolman RM; Dosland-Mullan BM
    J Heart Lung Transplant; 1998 Sep; 17(9):913-20. PubMed ID: 9773865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
    Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
    Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
    Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.
    Westall GP; Michaelides A; Williams TJ; Snell GI; Kotsimbos TC
    Transplantation; 2003 Jun; 75(12):2064-8. PubMed ID: 12829913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infections in lung allograft recipients: ganciclovir era.
    Valentine VG; Bonvillain RW; Gupta MR; Lombard GA; LaPlace SG; Dhillon GS; Wang G
    J Heart Lung Transplant; 2008 May; 27(5):528-35. PubMed ID: 18442719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
    Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
    Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center.
    Gould FK; Freeman R; Taylor CE; Ashcroft T; Dark JH; Corris PA
    J Heart Lung Transplant; 1993; 12(4):695-9. PubMed ID: 8396437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
    Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.